Compare GRFS & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRFS | PTGX |
|---|---|---|
| Founded | 1940 | 2006 |
| Country | Spain | United States |
| Employees | 25247 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 5.2B |
| IPO Year | N/A | 2016 |
| Metric | GRFS | PTGX |
|---|---|---|
| Price | $7.84 | $92.20 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 12 |
| Target Price | $10.15 | ★ $100.17 |
| AVG Volume (30 Days) | ★ 682.6K | 537.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 1.79% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.33 | $711.26 |
| Revenue Next Year | $6.50 | N/A |
| P/E Ratio | $18.67 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.19 | $39.60 |
| 52 Week High | $11.14 | $100.00 |
| Indicator | GRFS | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 27.72 | 53.45 |
| Support Level | $7.64 | $76.63 |
| Resistance Level | $9.11 | $94.89 |
| Average True Range (ATR) | 0.29 | 4.12 |
| MACD | -0.12 | 0.27 |
| Stochastic Oscillator | 2.99 | 38.54 |
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.